Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.50 |
| ▸ | GABRP | O00591 | 2/20 | 0.50 |
| ▸ | GABRD | O14764 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.50 |
| ▸ | GABRE | P78334 | 2/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781926 | 0.85 | GABRA1 (0.47) | GABRA1GABRB1GABRA2GABRB2GABRP | |
| SCHEMBL13327492 | 0.82 | G6PD (0.59) | MEN1KMT2AHSD17B3 | |
| SCHEMBL13642578 | 0.81 | G6PD (0.46) | MEN1KMT2AHSD17B3 | |
| SCHEMBL13642666 | 0.81 | G6PD (0.46) | MEN1KMT2AHSD17B3 | |
| SCHEMBL14570720 | 0.81 | G6PD (0.46) | MEN1KMT2AHSD17B3 | |
| SCHEMBL24481468 | 0.80 | GABRA1 (0.46) | GABRA1GABRB1GABRA2GABRB2GABRP | |
| SCHEMBL3116098 | 0.78 | GABRP (0.52) | GABRA1GABRB1GABRA2GABRB2GABRP | |
| SCHEMBL3115952 | 0.78 | GABRP (0.52) | GABRA1GABRB1GABRA2GABRB2GABRP | |
| SCHEMBL19781928 | 0.78 | GABRP (0.52) | GABRA1GABRB1GABRA2GABRB2GABRP | |
| SCHEMBL3115944 | 0.78 | GABRP (0.52) | GABRA1GABRB1GABRA2GABRB2GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021308-A9 | C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220002340-A1 | C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-20190233465-A1 | C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021308-A9 | C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | CNR1, CNR2, CYP21A2 | GABRA1 26/4885GABRB1 34/4885GABRA2 40/4885 |
| US-20190233465-A1 | C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | CNR1, CNR2, ADRA1B | GABRA1 30/4885GABRB1 39/4885GABRA2 42/4885 |
| US-20220002340-A1 | C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | CNR1, CNR2, CYP21A2 | GABRA1 26/4885GABRB1 34/4885GABRA2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.